These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1045 related items for PubMed ID: 22727222

  • 1. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S.
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [Abstract] [Full Text] [Related]

  • 2. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM.
    Int J Radiat Oncol Biol Phys; 2012 Jul 15; 83(4):e551-5. PubMed ID: 22417800
    [Abstract] [Full Text] [Related]

  • 3. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF, Senan S.
    Int J Radiat Oncol Biol Phys; 2012 May 01; 83(1):348-53. PubMed ID: 22104360
    [Abstract] [Full Text] [Related]

  • 4. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, Gomez D, Hahn SM, Roth JA, Mehran RJ, Heymach JV, Chang JY.
    Cancer; 2017 Aug 15; 123(16):3031-3039. PubMed ID: 28346656
    [Abstract] [Full Text] [Related]

  • 5. Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18FDG-PET/CT.
    Mazzola R, Fiorentino A, Di Paola G, Giaj Levra N, Ricchetti F, Fersino S, Tebano U, Pasetto S, Ruggieri R, Salgarello M, Alongi F.
    J Thorac Oncol; 2017 Mar 15; 12(3):547-555. PubMed ID: 28126325
    [Abstract] [Full Text] [Related]

  • 6. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
    Brooks ED, Sun B, Feng L, Verma V, Zhao L, Gomez DR, Liao Z, Jeter M, O'Reilly M, Welsh JW, Nguyen QN, Erasmus JJ, Eapen G, Ahrar K, Antonoff MB, Hahn SM, Heymach JV, Rice DC, Chang JY.
    JAMA Netw Open; 2018 Aug 03; 1(4):e181390. PubMed ID: 30646121
    [Abstract] [Full Text] [Related]

  • 7. Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC.
    van den Berg LL, Klinkenberg TJ, Groen HJM, Widder J.
    J Thorac Oncol; 2015 May 03; 10(5):826-831. PubMed ID: 25629639
    [Abstract] [Full Text] [Related]

  • 8. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.
    Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, Timmerman RD, McGarry RC.
    Lung Cancer; 2007 May 03; 56(2):229-34. PubMed ID: 17353064
    [Abstract] [Full Text] [Related]

  • 9. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun 03; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 10. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease.
    Verstegen NE, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S.
    Radiother Oncol; 2011 Nov 03; 101(2):250-4. PubMed ID: 22056535
    [Abstract] [Full Text] [Related]

  • 11. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM.
    Int J Radiat Oncol Biol Phys; 2010 Nov 15; 78(4):1033-9. PubMed ID: 20472359
    [Abstract] [Full Text] [Related]

  • 12. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I, Poon I, Yeung L, Erler D, Kim A, Keller B, Lochray F, Jain S, Soliman H, Cheung P.
    Clin Oncol (R Coll Radiol); 2014 Nov 15; 26(11):713-9. PubMed ID: 25085765
    [Abstract] [Full Text] [Related]

  • 13. Comparison of Single-fraction and Multi-fraction Stereotactic Radiotherapy for Patients with 18F-fluorodeoxyglucose Positron Emission Tomography-staged Pulmonary Oligometastases.
    Siva S, Kirby K, Caine H, Pham D, Kron T, Te Marvelde L, Whalley D, Stevens MJ, Foroudi F, MacManus M, Ball D, Eade T.
    Clin Oncol (R Coll Radiol); 2015 Jun 15; 27(6):353-61. PubMed ID: 25698068
    [Abstract] [Full Text] [Related]

  • 14. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.
    Ebright MI, Russo GA, Gupta A, Subramaniam RM, Fernando HC, Kachnic LA.
    J Thorac Cardiovasc Surg; 2013 Mar 15; 145(3):709-15. PubMed ID: 23317944
    [Abstract] [Full Text] [Related]

  • 15. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.
    Nakajima N, Sugawara Y, Kataoka M, Hamamoto Y, Ochi T, Sakai S, Takahashi T, Kajihara M, Teramoto N, Yamashita M, Mochizuki T.
    Ann Nucl Med; 2013 Apr 15; 27(3):261-70. PubMed ID: 23299492
    [Abstract] [Full Text] [Related]

  • 16. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L, Valeriani M, Nicosia L, Bracci S, De Sanctis V, Minniti G, Enrici RM, Osti MF.
    Anticancer Res; 2015 Nov 15; 35(11):6239-45. PubMed ID: 26504057
    [Abstract] [Full Text] [Related]

  • 17. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients.
    Toba H, Sakiyama S, Otsuka H, Kawakami Y, Takizawa H, Kenzaki K, Kondo K, Tangoku A.
    Interact Cardiovasc Thorac Surg; 2012 Nov 15; 15(5):859-64. PubMed ID: 22914804
    [Abstract] [Full Text] [Related]

  • 18. Patterns of Disease Recurrence after SABR for Early Stage Non-Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy.
    Verstegen NE, Lagerwaard FJ, Hashemi SM, Dahele M, Slotman BJ, Senan S.
    J Thorac Oncol; 2015 Aug 15; 10(8):1195-200. PubMed ID: 26200274
    [Abstract] [Full Text] [Related]

  • 19. Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment.
    Mattonen SA, Palma DA, Johnson C, Louie AV, Landis M, Rodrigues G, Chan I, Etemad-Rezai R, Yeung TP, Senan S, Ward AD.
    Int J Radiat Oncol Biol Phys; 2016 Apr 01; 94(5):1121-8. PubMed ID: 26907916
    [Abstract] [Full Text] [Related]

  • 20. Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy.
    Abelson JA, Murphy JD, Trakul N, Bazan JG, Maxim PG, Graves EE, Quon A, Le QT, Diehn M, Loo BW.
    Lung Cancer; 2012 Dec 01; 78(3):219-24. PubMed ID: 23009727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.